SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Kinnitas:
Kinnitatud elektroonselt
Koostas:
Allkiri
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Katrin Reimand
Osakonnajuhataja
04.04.2016
Kaja Vaagen
Vanemlaboriarst
04.04.2016
Ees- ja perekonnanimi
Ametikoht
kuupäev
Reference values for clinical chemistry tests
Analyte
Age
Reference range
Adrenocorticotropic hormone (PACTH)
Alanine aminotransferase (S,PALAT)
≥ 18 y
<2d
2d–<6d
6d–<7m
7m–<1y
1y–<4y
4y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
<4d
4 d – < 14 y
14 y – < 18 y
≥ 18 y
<4d
4 d – < 14 y
14 y – < 18 y
≥ 18 y
Morning 7.00–10.00 a.m
1.6–13.9
< 31
< 52
< 60
< 57
< 39
< 39
< 39
M < 26 F < 23
M < 50 F < 35
28–44
38–54
32–45
35–52
28–44
38–54
32–45
35–52
≥ 18 y
<1m
1m–<6m
6 m – < 16 y
16 y – < 41 y
41 y – < 61 y
<1m
1m–<1y
1y–<6y
6 y – < 11 y
11 y – < 16 y
≥ 16 y
All age groups
All age groups
100–350
< 0,025
< 0,015
< 0,005
< 0,007
< 0,008
< 21
< 3.8
< 3.3
< 2.7
< 2.1
M < 2.5 F < 3.5
< 30
< 20
Albumin (S,P-Alb)
Albumin (high sensitivity)
(S,P-Alb-hs)
Albumin in cerebrospinal fluid
CSF-Alb
CSF-Alb/S-Alb-hs
Albumin in urine
U-Alb/U-Crea
dU-Alb
10hU-Alb
Alcohol surrogates (P-Alcohol
surrogates)
Metanol (P-MetOH) All age groups
Etanol (P-EtOH)
Isopropanol (P-Isopropanol)
Propanol (P-Propanol)
Acetone (P-Acetone)
Etylenglycol (P-EG)
Propylenglycol (P-PG)
Aldosterone (S,P-Aldo)
4d–<8d
1m–<1y
1y–<2y
2 y – < 10 y
10 y – < 15 y
≥ 15 y
Lk - 1 -/ 23
< 0,01
< 0,2
< 0,01
< 0,01
< 0,01
< 0,02
< 0,02
supine 5.0–175.0
supine 5.0–90.0
supine 7.0–54.0
upright 5.0–80.0
upright 4.0–48.0
upright 3.7–43.2
Units
Reference
pmol/L
U/L
1, 2
1
g/L
1, 2
2, 5
g/L
2
2
mg/L
2
1
(2004)
1, 2
mg/mmoL
1
mg/d
µg/min
2
2
2
g/L
ng/dL
5
42
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Amylase (S,P-Amyl)
Amylase in urine
(U-Amyl)
Alpha-1-antitrypsin (S,P-AAT)
Alpha-fetoprotein (S-AFP)
Alkaline phosphatase (S,P-ALP)
Alkaline phosphatase, isoenzymes,
fraction activity
(S-ALP-isoE)
28–100
M 16–491 F 21–447
U/L
U/L
1, 2
2
<1m
1m–<7m
7m–<3y
3 y – < 20 y
≥ 20 y
<2d
2d–<3d
3d–<4d
4d–<5d
5d–<6d
6d–<7d
7d–<8d
8 d – < 15 d
15 d – < 22 d
22 d – < 29 d
29 d – < 1 m
1m–<2m
2m–<3m
3m–<4m
4m–<5m
5m–<6k
6k–<2y
2 y – < 18 y
≥ 18 y
Pregnant women
1.24–3.48
1.11–2.97
0.95–2.51
1.10–2.80
0.90–2.00
6500–140000
5800–116000
5000–107000
4400–91000
3800–80000
3300–69000
2900–61000
1200–49000
479–19000
264–5206
25–4793
13–1653
5–826
2,5–347
1,7–182
0,8–107
0,8–72
0,8–12
< 5.8
According to gestational
week
Result is considered in
complex of I trimester
pregnancy screening
83–248
122–469
142–335
129–417
M 116–469 F 57–254
M 82–331 F 50–117
M 55–149 F 45–87
M 40–130 F 35–105
egent 1 < 71
bone < 69
egent 2 < 13
intestine < 13
negative
Pre-dose (trough)
concentration:
therapeutic range 5–10
toxic > 10
Post-dose (peak)
concentration:
therapeutic range 20–25
toxic > 35
< 144
< 134
< 48
M 16–60 F 11–51
M 3.4–22.2 F 1.1–19.9
g/L
1
< 15 d
15 d – < 1 y
1 y – < 10 y
10 y – < 13 y
13 y – < 15 y
15 y – < 17 y
17 y – < 19 y
≥ 19 y
≥ 1 8y
All age groups
All age groups
Ammonia (P-NH4)
<2d
2d–<6d
6 d – < 18 y
≥ 18 y
<2y
Lk - 2 -/ 23
TÜL-14.5
PÜL-14
10
≥ 18 y
≥ 18 y
Amphetamines in urine (U-Amp)
Amikacin (S,P-Amic)
Androstenedione (S,P-Androst)
Tähis
Viide
Versioon
2
35
U/L
2, 44
U/L
µg/mL
2
µmol/L
1
(2004)
nmol/L
2
32
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
2y–<4y
4y–<6y
6y–<8y
8 y – < 10 y
10 y – < 12 y
12 y – < 14 y
14 y – < 16 y
16 y – < 18 y
≥ 18 y
≥ 18 y
M < 10.3
M < 5.8
M < 6.5
M < 4.5
M < 7.8
M < 9.5
M 1.6–12.2
M 3.4–14.6
M 1.4–9.1
8–52
Barbiturates in urine (U-Bar)
Benzodiazepines (S,P-Bzd)
<6y
6 y – < 18 y
≥ 18 y
<2d
2d–<6d
6d–<7m
7m–<1y
1y–<4y
4y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
All age groups
All age groups
Benzodiazepines in urine (U-Bzd)
Beta-2-microglobulin (S,P- β2-M)
All age groups
1d–<1m
6m–<1y
1y–<4y
4y–<7y
7 y – < 10 y
10 y – < 13 y
13 y – < 16 y
16 y – < 19 y
≥ 19 y
All age groups
< 150
< 240
< 200
< 122
< 110
< 84
< 89
< 56
< 52
< 51
M < 33 F < 27
M < 50 F < 35
negative
Therapeutic and toxic
concentrations of
different
benzodiazepines are
different, ask comment
from laboratory
negative
M 1603–4790
F 1722–4547
M 1423–3324
F 1024–3774
M 897–3095 F 999–2282
M 827–2228 F 742–2396
M 567–2260 F 546–2170
M 772–1712 F 736–1766
M 699–1836 F 704–1951
M 681–1954 F 787–1916
M 724–1874 F 555–1852
800–2200
< 0,6
≥ 18 y
< 2 d (full term)
2 d – < 3 d (full term)
3 d – < 4 d (full term)
4 d – < 7 d (full term)
< 2 d (preterm)
2 d – < 3 d (preterm)
3 d – < 6 d (preterm)
1 m – < 18 y
≥ 18 y
1 d – < 7 d (preterm)
>1m
1 y – < 17 y
< 10
< 150
< 193
< 217
< 216
< 140
< 205
< 410
< 17
< 21
< 10
≤5
M < 62 F < 83
Angiotensin-converting
enzyme (S,P-ACE)
Antistreptolysin O
(S,P-ASO)
Aspartate aminotransferase (S,PASAT)
1m–<6m
Betahydroxybutyrate (POCT) (BBHB POCT)
Bile acids (S,P-TBA)
Bilirubin (S,P-Bil)
Bilirubin (conjugated) (S,P-Bil-conj)
B-type natriuretic propeptide, N-
Lk - 3 -/ 23
F < 11.1
F < 11.3
F < 8.7
F < 5.3
F < 12.4
F 1.7–11.6
F 2.4–15.4
F 1.4–17.3
F 1.4–14.3
U/L
17
IU/mL
1
U/L
1, 2
1
1, 2
ng/mL
µg/L
3
mmol/L
2
45
µmol/L
µmol/L
2
1
2
pg/mL
1
2
1
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
terminal fragment (S,P-NT-proBNP)
≥ 17 y
Cocaine in urine (U-Coc)
C-peptide (S,P-C-pept)
C-reactive egent n
(S,P-CRP)
C-reactive egent n, high
sensitivity (S,P-CRP-hs)
All age groups
≥ 18 y
≥ 18 y
Dehydroepiandrosterone sulfate
(S,P-DHEAS)
<1w
1w–<1m
1m–<1y
1y–<5y
5 y – < 10 y
10 y – < 15 y
15 y – < 20 y
20 y – < 25 y
25 y – < 35 y
35 y – < 45 y
45 y – < 55 y
55 y – < 65 y
65 y – < 75 y
≥ 75 y
D-xylosis absorbation test (U-D-XylAT)
Delta amino-levulinic acid in urine
(U-DALA)
Delta amino-levulinic acid/creatinine
in urine (U-DALA/U-Crea)
Digoxin (S,P-Digox)
Erythropoietin (S,P-EPO)
<3w
2 m – < 16 y
≥ 18 y
TÜL-14.5
PÜL-14
10
< 125 (cut-off value for
excluding chronic egen
failure)
< 300 (cut-off value for
excluding acute egen
failure)
negative
0.37–1.47
<5
18
nmol/L
mg/L
< 4,1
mg/L
< 2,8
For cardiovascular
disease risk assessment:
low risk < 1.0
egent risk 1.0–3.0
high risk > 3.0
2.93–16.5
0.86–11.7
0.09–3.35
0.01–0.53
0.08–2.31
M 0.66–6.70 F 0.92–7.60
M 1.91–13.4 F 1.77–9.99
M 5.73–13.4 F 4.02–11.0
M 4.34–12.2 F 2.68–9.23
M 2.41–11.6 F 1.65–9.15
M 1.20–8.98 F 0.96–6.95
M 1.40–8.01 F 0.51–5.56
M 0.91–6.76 F 0.26–6.68
M 0.44–3.34 F 0.33–4.18
0–5 h > 1.2
g
≥ 18 y
< 34,3
≥ 18 y
µmol/mmol
Crea
Therapeutic level 0.9–2.0 ng/mL
Therapeutic level in case
of egen failure 0.6–1.2
Toxic > 2.0
M 1.7–17.9 F 2.1–15.9
U/L
M 3.5–21.9 F 2.9–8.5
M 3.1–22.2 F 2.8–16.5
M 5.3–31.0 F 4.0–21.6
M 3.7–18.8 F 3.3–15.8
4.3–29.0
< 0.2
g/L
negative
Therapeutic range10–30 µg/mL
Toxic > 40
Therapeutic range 10–20 µg/mL
Toxic > 20
12–327
µg/L
6–67
4–67
M 14–124 F 7–84
M 14–152 F 13–68
≥ 18 y
Ethanol (S,P-EtOH)
Ecstasy in urine (U-Ecs)
Phenobarbital (S,P-Phenobarb)
1y–<4y
4y–<7y
7 y – < 11 y
11 y – < 15 y
15 y – < 18 y
≥ 18 y
All age groups
All age groups
All age groups
Phenytoin (S,P-Phenyt)
All age groups
Ferritin (S,P-Fer)
<1y
1y–<4y
4y–<7y
7 y – < 13 y
13 y – < 18 y
Lk - 4 -/ 23
Tähis
Viide
Versioon
µmol/L
1, 2
1, 2
2
1, 2
31
< 3,9
18
3
32
23
1, 2
1, 2
1, 2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Folate (S,P-Fol)
Follicle stimulating
FSH)
egent n (S,P-
Phosphate (S,P-P)
18 y – < 61 y
5d–<1y
1y–<3y
3y–<6y
6y–<8y
8 y – < 12 y
12 y – < 14 y
14 y – < 18 y
18 y – < 66 y
< 10 y
<9y
10 y – < 14 y
9 y – < 14 y
14 y – < 18 y
≥ 18 y
<15 d
15 d – < 1 y
1y–<5y
5 y – < 13 y
13 y – < 16 y
16 y – < 19 y
≥ 19 y
Phosphate in urine
U-P (first morning urine)
dU-P
U-P/U-Crea
≥ 18 y
12 y – < 61 y
6m–<1y
1 y– < 2 y
2y–<3y
3y–<5y
5y–<7y
7 y – < 10 y
10 y – < 14 y
14 y – < 18 y
Gamma glutamyltransferase (S,P<2d
GGT)
2d–<6d
6d–<7m
7m–<1y
1y–<4y
4y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
Gamma-hydroxybutyrate in urine (U- All age groups
GHB)
Gentamicin (S,P-Genta)
All age groups
Glucose in egent/plasma, fasting
(fS,fP-Gluc)
Lk - 5 -/ 23
Preterm
< 2 d (full term)
2 d – < 4 d (full term)
4 d – < 18 y
≥ 18 y
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
M 30–400 F 13–150
> 23.9
nmol/L
> 8.7
> 27.0
> 29.7
> 25.9
> 27.0
> 18.0
10.4–42.4
M<3
U/L
F 0.5–4.5
M 0.3–4.0
F 0.4–6.5
M 0.4–7.4 F 0.8–8.5
M 1.5–12.4
F follic. egent 3.5–12.5
ovul egent 4.7–21.5
luteal egent 1.7–7.7
postmenop 25.8–134.8
1.71–3.15
mmol/L
1.47–2.54
1.33–2.06
1.28–1.82
F 1.00–1.70 M 1.11–1.88
0.94–1.55
0.87–1.45
13–44
13–42
1.2–19
1.2–14
1.2–12
1.2–8.0
1.2–5.0
1.2–3.6
0.8–3.2
0.8–2.7
< 151
< 185
< 204
< 34
< 18
< 23
< 17
M < 45 F < 33
M < 60 F < 40
negative
Pre-dose (trough)
concentration:
therapeutic range 0,5–2
toxic > 2
1.1–3.3
2.2–3.3
2.8–4.4
3.3–5.6
4.5–6.0
44
2
33
1, 2
44
2
mmol/L
mmol/d
mol/mol
1, 2
1, 2
4
U/L
1
1, 2
µg/mL
2
mmol/L
5
1
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
≥ 18 y
3.5–5.5
mmol/L
1
Glycated
i (B-HbA1c)
All age groups
2
2
13
1, 2
1
2
Glucose tolerance test (GTT):
• Glucose in serum/plasma,
fasting (fS,fP-Gluc 0 min)
All age groups
3,33–4,44
2,22–3,89
~0,6
< 0.8 ( egen urine)
< 1.1 (first morning urine)
4,8–5,9
29–42
Normal:
0 min < 6.1
120 min < 7.8
Diabetes:
0 min ≥ 7.0
120 min ≥ 11.1
Impaired glucose
tolerance (IGT):
0 min < 7.0
120 min ≥ 7.8…< 11.1
Impaired fasting glucose
(IFG):
0 min ≥ 6.1 …< 7.0
120 min < 7.8
mmol/L
CSF-Gluc/S,P-Gluc
Glucose in urine (U-Gluc)
< 18 y
≥ 18 y
≥ 18 y
≥ 18 y
Glucose in blood, fasting (fcB-Gluc)
Glucose in cerebrospinal fluid
CSF-Gluc
•
egent n
Glucose in serum/plasma,
120 min after oral
administration of glucose
(S,P-Gluc 120 min)
Acid-base balance (aB-ABB)
pH (aB-pH)
Oxygen, partial pressure (aB-pO2)
Carbon dioxide, partial pressure
(aB-pCO2)
Bicarbonate (aB-HCO3)
Base excess (aB-BE)
Haptoglobin (S,P-Hapto)
Hematocrit
Hemoglobin
Hemoglobin, fetal (B-HbF-neonat)
Hemoglobin in plasma (P-Hb)
Homocysteine (S,P-Hcy)
Monoclonal immunoglobulines in
egent (S-Monclon-Ig)
% of total Hb
mmol/mol
15
mmol/L
19
≥ 18 y
≥ 18 y
≥ 18 y
7.35–7.45
83–108
M 35–48 F 32–45
≥ 18 y
≥ 18 y
M 24–31 F 22–31
M (-2.7) –(+2.5)
F (-3.4)–(+1.4)
0.05–0.48
0.2–1.6
0.3–2.0
M 40–50 F 35–46
M 134–170 F 117–153
~80
< 40
< 10.0
< 7.6
< 8.4
< 10.4
N < 11.9 M < 13.4
< 12.0
Normal finding is
egent n for
monoclonal
immunoglobulines
Normal finding is
egent n for
monoclonal
immunoglobulines
< 0,83
0.20–1.00
0.27–1.95
0.34–3.05
0.53–2.04
0.58–3.58
<1m
1 m – < 18 y
≥ 1 8y
≥ 18 y
≥ 18 y
Newborns
≥ 18 y
5d–<1y
1y–<7y
7 y – < 12 y
12 y – < 15 y
15 y – < 19 y
≥ 19 y
All age groups
Monoclonal immunoglobulines in
urine (U-Monoclon-Ig)
All age groups
Immunoglobulin A (S,P-IgA)
<1y
1y–<4y
4y–<7y
7 y – < 10 y
10 y – < 12 y
12 y – < 14 y
Lk - 6 -/ 23
mmol/L
mmHg
mmHg
mmol/L
g/L
%
g/L
%
mg/L
µmol/L
5
2
11
11
19
24
44
2
g/L
2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Immunoglobulin G (S,P-IgG)
Immunoglobulin G in cerebrospinal
fluid (CSF-IgG)
Immunoglobulin G index (CSF-SIgG-ind)
Immunoglobulin M (S,P-IgM)
TÜL-14.5
PÜL-14
10
14 y – < 16 y
16 y – < 20 y
≥ 20 y
<1y
1y–<4y
4y–<7y
7 y – < 10 y
10 y – < 12 y
12 y – < 14 y
14 y – < 16 y
16 y – < 20 y
≥ 20 y
≥ 18 y
0.47–2.49
0.61–3.48
0.70–4.00
2.32–14.11
4.53–9.16
5.04–14.64
5.72–14.74
6.98–15.60
7.59–15.49
7.16–17.11
5.49–15.84
7.00–16.00
10–30
≥ 18 y
< 0.6
<1y
1y–<4y
4y–<7y
7 y – < 10 y
10 y – < 12 y
12 y – < 14 y
14 y – < 16 y
16 y – < 20 y
≥ 20 y
0.00–1.45
0.19–1.46
0.24–2.10
0.31–2.08
0.31–1.79
0.35–2.39
0.15–1.88
0.23–2.59
0.40–2.30
g/L
3.30–19.40
mg/L
Immunoglobulin free light chains:
• kappa free light chains (S,P- ≥ 18 y
IgKappa free)
• lambda free light chains
(S,P-IgLambda free)
• ratio: kappa free light
chains/lambda free light
chains
Insulin (S,P-Ins)
≥ 18 y
Insulin-like growth factor 1 (S,P-IGF1)
< 1y
1y
2y
3y
4y
5y
6y
7y
8y
9y
10 y
11 y
12 y
13 y
14 y
15 y
16 y
17 y
18 y
19 y
20 y
21 y − < 23 y
23 y − < 25 y
Lk - 7 -/ 23
Tähis
Viide
Versioon
g/L
2
mg/L
2
7
2
25
5.71–26.30
0.26–1.65
2.6–24.9
Women Men
16−143 13−138
19−160 18−176
22−178 23−212
25−198 28−247
29−219 34−282
34−244 40−316
39−271 46−349
45−302 53−382
52−336 60−414
59−371 68−443
67−407 75−469
75−440 83−490
82−467 90−505
89−488 96−514
94−501 101−516
98−505 104−512
101−502 107−502
102−493 109−488
103−478 109−472
102−461 109−453
100−441 108−432
95−419 105−411
89−376 100−369
mU/L
µg/L
1, 2
41
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Interleukin 6 (S-IL-6)
Potassium (S,P-K)
otassiu min urine
dU-K
U-K (first morning urine)
Calprotectin in faeces (St-Calpro)
Calcitonin (S,P-CT)
Calcium (S,P-Ca)
Calcium (ionized) (S,P-iCa)
Calcium in urine
dU-Ca
U-Ca/U-Crea
Cannabinoids in urine (U-THC)
Carbamazepine (S,P-Carba)
Carboxyhemoglobin (aB-COHb, cBCOHb)
Carcinoembryonic egent n (S,PCEA)
Carbohydrate egent n 15-3 (S,PCA 15-3)
Lk - 8 -/ 23
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
25 y − < 27 y
27 y − < 29 y
29 y − < 31 y
31 y − < 36 y
36 y − < 41 y
41 y − < 46 y
46 y − < 51 y
51 y − < 56 y
56 y − < 61 y
61 y − < 71 y
71 y − < 81 y
≥ 81 y
≥ 18 y
1d–<8d
8d–<1m
1m–<7m
7m–<1y
1y – < 18 y
≥ 18 y
83−336
78−303
74−278
69−260
65−236
59−215
54−199
48−187
43−176
37−170
34−168
31−176
< 3.4
3.2–5.5
3.4–6.0
3.5–5.6
3.5–6.1
3.3–4.6
3.4–4.8
6 y – < 10 y
10 y – < 15 y
≥ 15 y
≥ 18 y
6m–<2y
2y–<4y
≥4y
<3m
3m–<6m
6m–<9m
9 m – < 18 m
18 m – < 3 y
3 y – < 17 y
≥ 17 y
< 11 d
11 d – < 3 y
3 y – < 13 y
13 y – < 18 y
≥ 18 y
≥ 18 y
M 17–54 F 8–37
M 22–57 F 18–58
25–125
20–80
< 250
< 100
≤ 50
≤ 10
≤ 8.0
≤ 6.4
≤ 5.0
≤ 3.0
≤ 2.0
M ≤ 2.78 N ≤ 1.87
1.90–2.60
2.25–2.75
2.20–2.70
2.10–2.55
2.15–2.55
1.16–1.32
< 18 y
≥ 18 y
6m–<1y
1y–<2y
2y–<3y
3y–<5y
5y–<7y
7 y – < 18y
All age groups
All age groups
< 0.15
2.5–8.0
0.09–2.2
0.07–1.5
0.06–1.4
0.05–1.1
0.04–0.8
0.04–0.7
negative
Therapeutic range 4–12
Toxic > 15
0.5–1.5
≥ 18 y
20 y – < 70 y
≥ 18 y
94−330
89−297
84−270
77−250
72−225
65−210
59−200
54−197
48−194
43−195
38−194
35−183
Non-smokers < 3.8
Smokers
< 5.5
≤ 25
ng/L
mmol/L
32
1
5
mmol/d
5
mmol/L
µg/g
1, 2, 5
1
47
pmol/L
46
mmol/L
1
mmol/L
2
1
mmol/kg/d
mmol/d
mol/mol
1
1, 2
4
µg/mL
2
% of total Hb
5, 19
µg/L
1, 2
kU/L
1, 2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Carbohydrate egent n 19-9 (S,PCA 19-9)
Carbohydrate egent n 125 (S,PCA 125)
HE4 (S,P-HE4)
ROMA value
S-100 (S-S-100)
Growth egent n (S,P-GH)
Thyroid-stimulating
TSH)
egent n (S,P-
Chloride (S,P-Cl)
< 27
kU/L
1, 2
≥ 18 y
F < 35
kU/L
1, 2
Premenopausal
Postmenopausal
Premenopausal
< 70
< 140
< 11.4 low risk of finding
pmol/L
2
%
2
Postmenopausal
epithelial ovarian cancer
< 29.9 low risk of finding
epithelial ovarian cancer
µg/L
mU/L
1, 18
32
mU/L
42
1
mmol/L
1, 2
1
mmol/L
2
9
mmol/d
5
mmol/L
mmol/L
1, 2, 5
1
1
≥ 18 y
<7d
7d–<1m
1 m – < 18 y
≥ 18 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
1d–<7m
7m–<1y
1 y – < 18 y
≥ 18 y
<1y
1y–<6y
6 y – < 10 y
10 y – < 15 y
≥ 15 y
U-Cl (first morning urine)
≥ 18 y
Cholesterol (S,P-Chol)
1d–<1m
1m–<6m
6m–<1y
1y–<4y
4y–<7y
7 y – < 10 y
10 y – < 13 y
13 y – < 16 y
16 y – < 18 y
18 y – < 30 y
30 y – < 50 y
≥ 50 y
≥ 18 y recommended
HDL-Cholesterol (S,P-HDL-Chol)
≥ 18 y
≥ 18 y recommended
LDL-Cholesterol (S,P-LDL-Chol)
18 y – < 30 y
30 y – < 50 y
≥ 50 y
≥18 y recommended
Complement egent n 3 (S,P-C3) < 4 m
4m–<6m
≥6m
Complement egent n 4 (S,P-C4) < 4 m
Lk - 9 -/ 23
TÜL-14.5
PÜL-14
10
≥ 18 y
Chloride in sweat (Sw-Cl)
Chloride in urine
dU-Cl
Tähis
Viide
Versioon
≤ 0.105
18.0–168.0
18.0–114.0
< 18.0
< 30.0
0.70–15.2
0.72–11.0
0.73–8.35
0.70–5.97
0.60–4.84
0.51–4.30
0.27–4.2
97–108
97–106
97–107
98–107
normal < 30
borderline 30–60
cystic fibrosis > 60
2–10
15–40
M 36–110 F 18–74
M 64–176 F 36–173
110–250
46–168
M 1.40–3.90 F 1.60–4.01
M 2.09–3.80 F 1.60–3.65
M 1.97–4.63 F 1.97–5.59
M 2.20–4.71 F 2.79–4.99
M 2.84–5.61 F 2.74–4.99
M 2.84–5.46 F 2.69–5.43
M 2.72–5.77 F 2.72–5.64
M 2.35–5.28 F 2.79–5.30
M 2.12–4.97 F 2.38–6.05
2.9–6.1
3.3–6.9
3.9–7.8
< 5.0
M 0.8–2.1 N 1.0–2.7
M > 1.0 N > 1.2
1.2–4.3
1.4–4.7
2.0–5.3
<3
0.6–1.5
0.7–1.8
0.9–1.8
0.07–0.3
11
mmol/L
mmol/L
g/L
g/L
16
11
16
11
16
1
(2004)
1, 2
1
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Cholinesterase (S,P-ChE)
4m–<6m
≥6m
< 16 y
≥ 16 y
16 y - < 40 y
≥ 40 y
Pregnant egen, or
egen using oral
contraceptives (18 y –
< 42 y)
Chorionic gonadotropin (intact + β
subunit) (S,P-hCG intact + β
subunit)
Preterm neonates
<2m
2m–<1y
1y–<3y
3y–<5y
5y–<7y
7y–<9y
9 y – < 11 y
11 y – < 13 y
13 y – < 15 y
≥ 15 y
≥ 18 y
3y–<9y
9 y – < 13 y
13 y – < 18 y
≥ 18 y
5d–<8d
1m–<3m
3m–<1y
3 y – < 14 y
11 y – < 18 y
≥ 18 y
egent (S,P-CK)
Creatine egent, MB isoenzyme,
mass (S,P-CK-MBm)
Creatinine (S,P-Crea)
Creatinine in urine
U-Crea (first morning urine)
dU-Crea
Creatinine clearance
Lk - 10 -/ 23
0.08–0.3
0.1–0.4
5320–12920
M 5320–12920
F 4260–11250
F 5320–12920
F 3650–9120
<2d
2d–<6d
6d–<7m
7m–<1y
1y–<4y
4y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
≥ 18 y
<2y
2 y – < 11 y
Creatine
TÜL-14.5
PÜL-14
10
M < 2.6
F nonpregnant < 5.3
postmenopausal < 8.3
During pregnancy
according to weeks of
gestation
Result is considered in
complex of I trimester
pregnancy screening
5–11 a.m 30–910
5–11 p.m 30–800
5–11 a.m 30–880
5–11 p.m 30–640
5–11 a.m 30–750
5–11 p.m 30–560
6–10 a.m 172–497
4–8 p.m 74–286
< 712
< 652
< 295
< 203
< 228
< 149
M < 247 F < 154
M < 270 F < 123
M < 308 F < 192
M < 6.22 F < 4.88
Chorionic gonadotropin, free β
subunit (S-fβ-hCG)
Cortisol (S,P-Cort)
Tähis
Viide
Versioon
U/L
(2004)
1,2
1, 2
mIU/mL
1, 18
U/L
nmol/L
3
1, 2
U/L
1
ng/mL
2
18
29–87
27–77
14–34
15–31
23–37
25–42
30–47
29–56
39–60
40–68
M 59–104 F 45–84
µmol/L
2
M 3.5–24.6 F 2.5–20.0
0.97–6.0
1.5–12.5
2.6–16.5
M 9.0–19.0 F 6.0–13.0
> 38
> 54
> 64
> 120
mmol/L
mmol/d
2
3
mL/min/1,73m
2
2
1
(2004)
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Estimated glomerular filtration rate
(eGFR)
Cryoglobulins (S-Cryo)
Uric acid (S,P-UA)
Uric acid in urine
dU-UA
U-UA (first morning urine)
Lactate dehydrogenase (S,P- LDH)
Lactate dehydrogenase in pleural
fluid (PlrF-LDH)
expressed by ratio
PlrF-LDH/S,P-LDH
Lactate
vP-Lac
aP-Lac
Lactate in cerebrospinal fluid (CSFLac)
Lactose tolerance test (LTT)
66–143
≥ 90
mL/min
2
mL/min/1,73m
2
12
≥ 18 y
1d–<1m
1m–<1y
1y–<4y
4y–<7y
7 y – < 10 y
10 y – < 13 y
13 y – < 16 y
16 y – < 18 y
≥ 18 y
< 50
M 71–230
M 71–330
M 124–330
M 106–325
M 106–319
M 130–342
M 183–413
M 124–448
M 202–417
µg/mL
µmol/L
1
≥ 18 y
≥ 18 y
<2d
2d–<6d
6d–<7m
7m–<1y
1y–<4y
4y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
All age groups
1.2–5.9
2.2–5.5
< 1327
< 1732
< 975
< 1100
< 850
< 615
M < 764 F < 580
M < 683 F < 436
240–480
Transudate < 0.6
Exudate > 0.6
mmol/d
mmol/L
U/L
≥ 18 y
≥ 18 y
<3d
3 d – < 11 d
11 d – < 18 y
≥ 18 y
All age groups
< 2.2
< 1.6
1.1–6.7
1.1–4.4
1.1–2.8
1.1–2.4
A rise in the blood
glucose concentration
> 1.1 mmol/L indicates
the absence of lactase
deficiency
Absent in normal
cerebrospinal fluid
Therapeutic 0.6–1.2
Toxic > 2
< 34
< 31
< 55
13–60
M < 0.10
F < 0.45
M < 0.44
F < 3.36
M < 2.28
F < 5.65
M 0.31–5.29 F < 11.00
M 0.15–5.33 F < 15.80
M 1.7–8.6
F follic.phase 2,4–12,6
ovulat egent 14–95,6
lut.phase
1.0–11.4
mmol/L
1, 2
mmol/L
1, 2
All age groups
Lipase (S,P-Lip)
<1m
1 m – < 13 y
16 y – < 18 y
≥ 18 y
1y–<8y
8 y – < 10 y
10 y – < 12 y
12 y – < 15 y
15 y – < 18 y
≥ 18 y
egent n (S,P-LH)
Lk - 11 -/ 23
TÜL-14.5
PÜL-14
10
≥ 18 y
≥ 18 y
Oligoclonal immunoglobulins in
cerebrospinal fluid (CSF-Ig-oligo)
Lithium (S-Li)
Luteinizing
Tähis
Viide
Versioon
≥ 18 y
F 59–271
F 65–319
F 106–295
F 118–301
F 106–325
F 148–348
F 130–378
F 142–389
F 143–339
2
1, 2
1, 2
1
2
13
20
mmol/L
2
1
U/L
U/L
2
33
1, 2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Magnesium (S,P-Mg)
Magnesium in urine
dU-Mg
U-Mg
Methadone in urine (U-Mtd)
Metamphetamines in urine (U-Met)
Methemoglobin (aB-MetHb, cBMetHb)
Methotrexate (S,P-MTX)
Sodium in urine
dU-Na
U-Na (first morning urine)
Neutrophil gelatinase-associated
lipocalin in urine (U-NGAL)
Opiates in urine (U-Mop)
Osmolality (S-Osmol)
Osmolality in urine (U-Osmol)
Parathyroid egent n (S-PTH)
Paracetamol (S,P-Paracet)
Lk - 12 -/ 23
TÜL-14.5
PÜL-14
10
2d–<5d
5m–<6y
6 y – < 12 y
12 y – < 20 y
20 y – < 60 y
60 y – < 90 y
≥ 90 y
postmenop
0.62–0.91
0.70–0.95
0.70–0.86
0.70–0.91
0.66–1.07
0.66–0.99
0.70–0.95
≥ 18 y
≥ 18 y
All age groups
All age groups
≥ 18 y
3.0–5.0
1.7–5.7
negative
negative
0.2–0.6
≥ 18 y
<8d
8d–<2m
2m–<7m
7m–<1y
1 y – < 18 y
≥ 18 y
Therapeutic range
µmol/L
depends on dose of MTX
and specimen collecting
time:
4 h < 150
36 h < 3
42 h < 1
48 h < 0.4
54 h < 0.25
Depends on the type of
transplantate and
concominant
administration of some
other drugs
M 28–72 F 25–58
ng/mL
131–144
mmol/L
132–142
132–140
131–140
132–141
136–145
6 y – < 10 y
10 y – < 15 y
≥ 15 y
≥ 18 y
≥ 18 y
M 41–115 F 20–69
M 63–177 F 48–168
M 40–220 F 27–287
54–190
≤ 131,7
All age groups
negative
18 y – < 61 y
≥ 61 y
≥ 18 y
2y–<4y
4y–<6y
6y–<8y
8 y – < 10 y
10 y – < 12 y
12 y – < 14 y
14 y – < 15 y
≥ 15 y
≥ 18 y
275–295
280–300
400–800
M 0.6–3.6 F 0.4–3.4
M 0.5–1.7 F 0.1–1.4
M 0.3–2.8 F 0.3–2.6
M 0.5–3.6 F 0.2–3.2
M 0.3–2.6 F 0.5–3.6
M 0.2–2.7 F 0.2–3.9
M 0.5–3.8 F 0.1–4.1
M, F 1.6–6.9
Therapeutic range 10–30
Mycophenolic acid (P-MPA)
Myoglobin (S,P-Myogl)
Sodium (S,P-Na)
Tähis
Viide
Versioon
7.7–58.5
mmol/L
2
mmol/d
mmol/L
2
% of total Hb
19
21
2
1, 18
1
2
mmol/d
5
mmol/L
ng/mL
1
39
mosm/kgH2O
1
mosm/kgH2O
pmol/L
1
1
µg/mL
1, 2
2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Toxic > 200
(4 h after administration)
> 100
(8 h after administration)
> 50
(12 h after
administration)
Porphobilinogen in urine
U-PBG
U-PBG/U-Crea
Porphyrines in urine
U-Porph
U-Porph/U-Crea
Prealbumin (S-PreAlb)
Progesterone (S,P-Prog)
≥ 18 y
≥ 18 y
< 8,84
< 1,4
µmol/L
µmol/mmol
31
≥ 18 a
≥ 18 a
<1m
1m–<7m
7m–<7y
≥7y
1d–<8d
8 d – < 16 d
16 d – < 4 y
4y–<7y
7y–<9y
9 y – < 11 y
11 y – < 12 y
12 y – < 13 y
13 y – < 14 y
14 y – < 15 y
15 y – < 16 y
16 y – < 17 y
17 y – < 18 y
≥ 18 y
20–320
< 34
0,07–0,39
0,08–0,34
0,12–0,36
0,20–0,40
M 1.0–12.4 F 1.0–9.5
M 1.0–8.3
F 1.0–4.8
M < 3.5
F < 3.2
M < 8.6
F < 3.5
M 0.6–3.5
F 1.0–3.5
M < 3.8
F < 3.5
M 0.6–3.5
F 1.0–2.9
M 1.0–5.1
F 1.6–6.0
M 1.3–4.8
F 1.3–4.8
M 1.0–4.1
F 1.6–41.7
M 1.9–9.5
F 1.6–45.8
M 2.2–14.6 F 1.9–46.7
M 2.2–8.9
F 2.2–41.3
M 0.7–4.3
F follic.phase 0.6–4.7
ovulat.phase 2.4–9.4
lut.phase
5.3–86
postmenop. 0.3–2.5
< 0,05
Value > 2 is indicative for
sepsis
M1028–8650F 475–8014
M 854–5894 F 918–7017
M 208–1558 F 125–1342
M 51–305 F 57–426
M 53–526 F 66–348
M 89–284 F 68–560
M 49–348 F 51–937
M 74–286 F 61–329
M 66–394 F 98–483
M 87–371 F 72–659
M 91–420 F 98–435
M 68–320 F 53–439
M 38–350 F 70–377
M 86–324 F 102–496
< 1.4
< 2.0
< 3.1
< 4.1
< 4.4
> 15
nmol/L
nmol/mmol
g/L
31
1
nmol/L
1, 2
32
Procalcitonin (S,P-PCT)
≥3d
Prolactin (S,P-Prol)
1d–<8d
8 d – < 16 d
16 d – < 4 y
4y–<7y
7y–<9y
9 y – < 11 y
11 y – < 12 y
12 y – < 13 y
13 y – < 14 y
14 y – < 15 y
15 y – < 16 y
16 y – < 17 y
17 y – < 18 y
≥ 18 y
< 40 y
40 y – < 50 y
50 y – < 60 y
60 y – < 70 y
≥ 70 y
All age groups
Prostate-specific
PSA)
egent n (S,P-
Free prostate-specific
(S,P-fPSA%)
Lk - 13 -/ 23
egent n
1, 2
ng/mL
18, 26
mU/L
32
µg/L
2
1, 2
%
2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Pregnancy assotiated
(S-PAPP-A)
egent n A
Iron (S,P-Fe)
Rheumatoid factor (S,P-RF)
Salicylates (S,P-Salic)
1d–<1m
1m–<1y
1y–<4y
4 y –- < 7 y
7 y – < 10 y
10 y – < 13 y
13 y – < 16 y
16 y – < 19 y
≥ 19 y
14 d – < 4 m
4m–<1y
1y–<3y
3y–<5y
5y–<7y
7 y – < 11 y
11 y – < 15 y
15 y – < 18 y
≥ 18 y
≥ 18 y
≥ 18 y
Sirolimus (B-Sirolimus)
All age groups
Renin (P-Renin)
Sex egent n-binding
(S,P-SHBG)
egent n
1d–<8d
8 d – < 16 d
16 d – < 4 y
4y–<7y
7y–<9y
9 y – < 11 y
11 y – < 12 y
12 y – < 13 y
13 y – < 14 y
14 y – < 15 y
15 y – < 16 y
16 y – < 17 y
17 y – < 50 y
Lk - 14 -/ 23
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Result is considered in
complex of I trimester
pregnancy screening
M 5.7–20.0 F 5.2–22.7
M 4.8–19.5 F 4.5–22.6
M 5.2–16.3 F 4.5–18.1
M 4.5–20.6 F 5.0–16.7
M 4.8–17.2 F 5.4–18.6
M 5.0–20.0 F 5.7–18.6
M 4.7–19.7 F 5.4–19.5
M 4.8–24.7 F 5.9–18.3
M 10.6–28.3 F 6.6–26.0
11.2–147.9 supine
17.4–173.8 supine
21,4–102,3 supine
19.5–123.0 supine
20.4–128.8 supine
14.8–102.3 supine
13.8–104.7 supine
13.8–72.4 supine
5.3–99.1 upright
< 14
Therapeutic range:
antipyretic, analgetic
30–100
anti-inflammatory
150–300
Toxic > 300
lethal > 600
Therapeutic range
depends on indications of
Sirolimus administration
and specimen collection
time
M 8.8–50.7
F 7.4–34.8
M 13.7–68.7
F 10.1–51.2
M 19.8–114.4
F 12.9–96.6
M 34.4–141.1
F 42.5–130.8
M 42.9–120.3
F 41.8–149.4
M 30.3–169.0
F 30.4–178.1
M 46.9–153.5
F 34.9–158.0
M 30.8–173.6
F 30.6–144.1
M 22.9–159.0
F 25.2–160.0
M 14.6–100.6
F 13.4–134.3
M 17.8–142.7
F 25.1–154.8
M 17.9–113.1
F 28.0–164.4
M 18.3–54.1 F 32.4–128
U/L
µmol/L
1
µU/mL
1
43
IU/mL
µg/mL
42
1, 2
1, 2
nmol/L
32
2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Free androgen index (FAI)
M 20.6–76.7 F 27.1–128
20 y – < 50 y
M 38.7–91,7
F 0.340–3.87
M 27.0–65,5
F 0.164–2.38
Therapeutic range
depends on indications of
Tacrolimus
administration and
specimen collection time
Therapeutic range for
bronchodilatation:
10–20
10–15
Treatment of neonatal
apnoe:
7–12
Toxic:
> 20
> 15
M 0.42–0.72
M 0.10–1.12
M 0.10–2.37
M 0.98–38.5
M 11.4–27.9
F 0.278–1.73
M 9.47–28.3
F 0.104–1.39
1.3–3.6
2.0–3.6
15–45
4.1–7.7
F 1.9–4.4
M 2.2–5.0
< 0.7
0.45–2.6
recommended < 1.7
1.12–4.43
1.23–4.22
1.32–4.07
1.42–3.80
1.43–3.55
1.40–3.34
1.30–3.10
2.65–9.68
3.00–9.28
3.30–8.95
3.69–8.46
3.88–8.02
3.93–7.70
3.10–6.80
I trim 3.8–6.0
II trim 3.2–5.5
III trim 3.1–5.0
negative
All age groups
Theophylline (S,P-Theoph)
≥ 18 y
< 18 y
Testosteron (S,P-Testo)
≥ 18 y
Neonates
<1y
1y–<7y
7 y – < 13 y
13 y – < 18 y
18 y – < 50 y
≥ 50 y
Transferrin (S,P-Transf)
Transferrin saturation
Soluble transferrin receptor (S,PTransf-sR)
Triglycerides (S,P-Trigl)
Triiodthyronine (S,P-T3)
Free triiodthyronine (S,P-fT3)
<7d
≥1y
9m–<1y
18 y – < 46 y
18 y – < 61y
Preterm neonates
≥ 18 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
Pregnancy
Tricyclic antidepressants in urine (U- All age groups
TCA)
Troponin T (high sensitivity) (S,P≥ 18 y
cTnT-hs)
Lk - 15 -/ 23
TÜL-14.5
PÜL-14
10
≥ 50 y
≥ 50 y
Tacrolimus (B-Tacro)
Tähis
Viide
Versioon
< 14
≥ 14 myocardial necrosis
%
2
ng/mL
mg/L
1, 2
nmol/L
1, 2
g/L
1
(2004)
2
22
2
%
mg/L
mmol/L
nmol/L
1
11
16
1
pmol/L
1, 2
1
1, 2
1
ng/L
18
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Ceruloplasmin (S,P-Cer)
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Zinc (S-Zn)
<5m
5m–<7m
7m–<4y
4 y – < 13 y
13 y – < 20 y
≥ 20 y
≥ 18 y
Zinc in seminal fluid (SemF-Zn)
≥ 18 y
0.15–0.56
g/L
0.26–0.83
0.31–0.90
0.25–0.45
M 0.15–0.37 F 0.22–0.50
M 0.15–0.30 F 0.16–0.45
M 11.1–19.5
µmol/L
F 10.7–17.5
0.31–1.53
mmol/L
Zinc in urine (dU-Zn)
≥ 18 y
4.65–12.30
µmol/d
14
Antibodies to cyclic citrullinated
egent n (S,P-CCP IgG)
Cyclosporin A (B-CyA)
All age groups
< 17
kU/L
2
All age groups
ng/mL
2
Cystatin C (S,P-CysC)
<1m
1m–<1y
1 y – < 20 y
20 y – < 71 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
All age groups
Therapeutic range
depends on indications of
CyA administration and
specimen collection time
1.1–2.2
0.5–1.4
0.5–1.0
0.47–1.09
25–307
20–228
18–125
9.0–67
5.1–43
2.6–36
1.4–78
< 134
< 146
< 130
< 38
< 37
< 64
< 115
< 117
< 47
< 32
< 13
< 18
< 26
< 34
< 1.22
mg/L
1
µg/L
2
1
kU/L
1, 2
1
kU/L
1, 2
1, 2
U/L
2
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
<6d
6d–<4m
4m–<1y
1y–<7y
7 y – < 12 y
12 y – < 21 y
≥ 21 y
64.9–239
69.6–219
73.0–206
76.6–189
77.1–178
76.1–170
66.0–181
11.0–32.0
11.5–28.3
11.9–25.6
12.3–22.8
12.5–21.5
12.6–21.0
12.0–22.0
nmol/L
1, 2
pmol/L
1
Thyroglobulin (S,P-TG)
Antibodies to thyroglobulin (S-TG
Ab)
Antibodies to thyroid peroxidase
(S,P-TPO Ab)
Antibodies to TSH receptor (S-TR
IgG)
Thyroxine (S,P-T4)
Free thyroxine (S,P-fT4)
Lk - 16 -/ 23
2
14
1, 2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Pregnancy
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Protein fractions in urine
(electrophoresis) (U-Prot-Fr)
All age groups
Urea (S,P-Urea)
1y–<4y
4 y – < 14 y
14 y – < 20 y
≥ 20 y
I trim 12.1–19.6
II trim 9.6–17.0
III trim 8.4–15.6
Results will be
commented by laboratory
doctor
1.8–6.0
mmol/L
2.5–6.0
2.9–7.5
< 8.1
≥ 18 y
≥ 18 y
<7d
7m–<1y
1y–<3y
3 y – < 18 y
≥ 18 y
1d–<2m
2m–<4m
4m–<7m
7m–<1y
1y–<3y
3y–<5y
5y–<9y
≥ 18 y
< 714
286–595
44–76
51–73
56–75
60–80
64–83
0.25–0.72
0.20–0.72
0.15–0.50
0.10–0.45
0.10–0.40
0.10–0.38
0.10–0.43
0.15–0.45
Urea in urine
dU-Urea
U-Urea (first morning urine)
Protein (S,P-Prot)
Protein in cerebrospinal fluid (CSFProt)
Protein in pleural fluid (PlrF-Prot)
PlrF-Prot/S,P-Prot
≥ 18 y
≥ 18 y
≥ 18 y
Vancomycin (S,P-Vanco)
≥ 18 y
Bicarbonate (S,P-HCO3)
Vitamiin B12 (S,P-Vit B12)
≥ 18 y
5d–<1y
1y–<9y
9 y – < 14 y
14 y – < 17 y
17 y – < 19 y
≥ 19 y
All age groups
1 y – < 10 y
≥ 18 y
Unconjugated estriol (S-E3 unconj)
Lk - 17 -/ 23
1
2
mmol/d
mmol/L
g/L
1, 2
1, 2
1
g/L
1
g/L
2
13
g/d
mg/mg Crea
µg/mL
2
27
1, 2
µg/mL
40
mmol/L
pmol/L
1
44
transudate < 0.5
exudate > 0.5
Protein in urine
dU-Prot
U-Prot/U-Crea
Valproic acid (S,P-Valpr)
Vitamiin D (S,P-Vit D(25-OH))
Estradiol (S,P-E2)
1
< 0.15
< 0.2
Therapeutic range 50–
100
Toxic > 150
Pre-dose (trough)
concentration:
therapeutic range 15–20
22–29
191–1163
209–1190
186–830
180–655
150–655
145–569
Optimal > 75
M < 73.4 F 22–99.1
M < 223
F egen.phase 45–854
ovulat.phase151–1461
lut.phase 82–1251
postmenop. < 183
Result is considered in
complex of I trimester
pregnancy screening
2
nmol/L
pmol/L
µg/L
1, 2
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Tests forwarded to other laboratories
Analyte
Age
Reference range
Units
17-alpha-hydroxyprogesterone (S17-OHP)
<1m
<2m
1m–<5m
2m–<5m
5 m –- < 3 y
3y–<6y
6y–<9y
9 y – < 12 y
12 y – < 15 y
15 y – < 17 y
≥ 17 y
F 0.2–3.2
M 0.0–6.1
F 0.2–3.2
M 0.1–2.7
M 0.0–5.5 F 0.0–6.4
M 0.0–6.2 F 0.0–8.5
M 0.0–1.9 F 0.0–2.2
M 0.0–2.4 F 0.0–3.9
M 0.6–4.2 F 0.3–6.3
M 0.7–5.8 F 0.0–8.8
M 0.0–4.2
F follic. phase 0.5–2.1
lut. phase 1.1–8.8
M 1.43–11.6
F 1.66–9.49
F 1.18–9.16
F 0.672–7.55
F 0.78–5.24
F 0.097–2.96
F 0.046–2.06
M 37.1–72,1
F 38.6–80.3
nmol/L
Performer: synlab Estonia
Anti-Myller Hormone (S,P-AMH)
Performer: East Tallinn Central Hospital
Apolipoprotein A1 (fS-ApoA1)
≥ 18 y
20 y – < 25 y
25 y – < 30 y
30 y – < 35 y
35 y – < 40 y
40 y – < 45 y
45 y – < 51 y
≥ 18 y
Reference
ng/mL
µmol/L
Performer: North Estonia Medical centre
Apolipoproteiin B (fS-ApoB)
≥ 18 y
M 1.29–2.59
F 1.17–2.28
µmol/L
30 y – < 51 y
51 y – < 71 y
≥ 71 y
Premenopaus
Postmenopaus
≥ 18 y
M 0.016–0.584
M 0.096–0.704
M 0.066–0.854
F 0.025–0.573
F 0.104–1.008
2–8
ng/mL
6.2–54.8
pmol/L
Performer: North Estonia Medical centre
C-telopeptides (S,P-C-telo)
Performer: North Estonia Medical centre
5-hydroxy-indole acetic acid in 24h
urine (dU-5-HIAA)
mg/d
Performer: Departement of Pharmacology,
Tartu University
Gastrin (S-Gastr)
Performer: East Tallinn Central Hospital
Hemoglobine fractions (B-Hb-Fr
screen, B-Hb-Fr conf)
All age groups
Results will be
commented by
laboratory doctor
All age groups
< 10
<1y
1y–<3y
3y–<6y
6 y – < 12 y
12 y – < 18 y
≥ 18 y
1.51–7.92
2.65–9.38
3.62–12.28
3.77–11.31
3.62–10.27
4.05–10.11
Performer: North Estonia Medical centre
21-hydoxylase autoantibodies (S21OH Ab)
Performer synlab Estonia
Immunoglobulin G subclasses
S-IgG1
Lk - 18 -/ 23
g/L
1, 18
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
S-IgG2
<1y
1y–<3y
3y–<6y
6 y – < 12 y
12 y – < 18 y
≥ 18 y
0.26–1.36
0.28–2.16
0.57–2.90
0.68–3.88
0.81–4.72
1.69–7.86
S-IgG3
<1y
1y–<3y
3y–<6y
6 y – < 12 y
12 y – < 18 y
≥ 18 y
0.09–0.92
0.09–0.86
0.13–0.79
0.16–0.89
0.14–1.06
0.11–0.85
S-IgG4
<1y
1y–<3y
3y–<6y
6 y – < 12 y
12 y – < 18 y
≥ 18 y
0.004–0.46
0.009–0.74
0.01–1.45
0.01–1.70
0.05–1.99
0.03–2.01
<3y
3y–<5y
5y–<7y
7y–<8y
8y–<9y
9 y – < 10 y
10 y – < 11 y
11 y – < 12 y
12 y – < 13 y
13 y – < 17 y
17 y – < 18 y
18 y – < 31 y
31 y – < 61 y
61 y – < 76 y
≥ 76 y
All age groups
0.7–3.9
0.9–4.7
1.2–5.5
1.4–6.1
1.6–6.5
1.8–7.1
2.1–7.7
2.4–8.4
2.7–8.9
3.0–10.0
3.2–8.7
3.0–7.8
3.3–7.0
2.8–6.6
2.2–5.0
< 0.4
mg/L
< 6.9
U/mL
25–312
35–445
µg/d
Performer: East Tallinn Central Hospital
Insulin like growth factor binding
protein 3 (S-IGFBP3)
Performer: synlab Estonia
Insulin antibodies (S-IAA IgG)
U/mL
Performer: synlab Estonia
Carbohydrate
egent n CA 72-4
Performer: synlab Estonia
Catecholamine metabolites in
urine :
Metanephrine (dU-Metnef)
Normetanephrine (dU-Normet)
Performer: East Tallinn Central Hospital
Circulating immune complexes
(C1q) (S-CIC(C1q))
Clozapine (S,P-Clozap)
All age groups
Negative
All age groups
Therapeutic: 350–700
Toxic: > 1000
ng/mL
All age groups
> 70
CH50 Eq
U/mL
All age groups
0.21–0.39
g/L
Performer : Departement of Pharmacology,
Tartu University
Classical complement pathway
CH50 activity (S-CH50)
Performer: East Tallinn Central Hospital
Complement C1 inhibitor (S-C1
Lk - 19 -/ 23
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
Inhibitor)
Performer: East Tallinn Central Hospital
Complement C1 inhibitor funciton
(S-C1 Inhibitor func)
All age groups
> 68
%
≥ 18 y
7.00–8.00 1.38–15.7
12.00–13.00 0.55–9.94
16.00–17.00 0.55–6.62
22.00–23.00 0.55–3.59
3.9–55.2
7.2–102.0
11.0–154.6
M 11.6–165.6
F 8.3–118.7
< 100
nmol/L
Performer: East Tallinn Central Hospital
Cortisol in saliva (Sal-Cort
Performer synlab Estonia
Cortisol in urine (dU-Cort)
<8y
8 y – < 12 y
12 y – < 17 y
≥ 17y
Performer synlab Estonia
Chromogranin A (P-CgA)
≥ 18 y
nmol/d
µg/L
Performer: North Estonia Medical centre
Lamotrigine (S,P-Lamotr)
≥ 18 y
Therapeutic 1.5 – 15
Toxic > 20
µg/mL
All age groups
F < 12
M<6
µg/L
≥ 18 y
< 75
nmol/L
≥ 18 y
< 90
ng/L
< 17
ng/mL
≥ 18 y
< 180
ng/L
All age groups
Concentration of MHD
3–35
µg/mL
≥ 18 y
< 44
mg/d
18 y – < 30 y
30 y – < 51 y
51 y – < 71 y
Premenop. (≥ 21y)
Postmenop.
M 24–70
M 14–42
M 14–46
F 11–43
F 15–46
> 200
ng/mL
≤ 1.3
> 1.6 refers to alcohol
consuming
%
Performer : Departement of Pharmacology,
Tartu University
Leptin (S-Leptin)
Performer : synlab Estonia
Lipoprotein a (S,P-Lp(a))
Performer: North Estonia Medical centre
Metanephrine (P-Meta)
Performer synlab Estonia
Neuronspecific enolase (S-NSE)
Performer: North Estonia Medical centre
Normetanephrine (P-Normeta)
Performer synlab Estonia
Oxcarbazepine (S,P-Oxcarb)
Performer : Departement of Pharmacology,
Tartu University
Oxalic acid in urine (dU-Oxal)
Performer synlab Estonia
Osteocalcin (S,P-Osteoca)
Performer: North Estonia Medical centre
Pancreatic elastase 1 in stool (StpE1)
µg/g
Performer: East Tallinn Central Hospital
Carbohydrate deficient transferrin
(S-CDT)
Performer: North Estonia Medical centre
Thiopurine methyltransferase in
erythrocytes (RBC-TPMT)
Lk - 20 -/ 23
≥ 18 y
Concentration of 6methylmercaptopurine
after 60 min of
ng/mL
1, 18
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
Performer : Departement of Pharmacology,
Tartu University
Citrate in urine (dU-Citr)
TÜL-14.5
PÜL-14
10
incubation
59–110
≥ 18 y
< 1.7
mmol/d
<4m
4m–<7m
7m–<1y
1y–<6y
6 y – < 10 y
10 y – < 14 y
14 y – < 20 y
≥ 20 y
≥ 18 y
1.4–7.2
4–17
8–21
13–24
13–21
13–19
M 10–18 F 11–25
M 11–22 F 12–24
0.16–0.94
µmol/L
5
µmol/d
5
<1y
1y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
<1y
1y–<7y
7 y – < 13 y
13 y – < 18 y
≥ 18 y
All age groups
0.20–0.50
0.20–0.50
0.25–0.60
0.25–0.70
0.30–0.70
1–8
3–9
4–9
5–18
5–20
25–75
µg/mL
µg/L
All age groups
5–50
µg/L
1.0–5.5
µg/mL
Performer synlab Estonia
Copper (S-Cu)
Performer: Estonian Veterinary and Food
Laboratory
Copper in urine (dU-Cu)
Performer: Estonian Veterinary and Food
Laboratory
Vitamiin A (S,P-Vit A)
Performer : Departement of Pharmacology,
Tartu University
Vitamiin E (S,P-Vit E)
Performer : Departement of Pharmacology,
Tartu University
Vitamiin B1 (B-Vit B1)
µg/mL
Performer : Departement of Pharmacology,
Tartu University
Vitamiin B6 (B-Vit B6)
Performer : Departement of Pharmacology,
Tartu University
Voriconazole (S,P-Voricon)
Performer : Departement of Pharmacology,
Tartu University
References
1
2
3
4
5
6
W.Heil, R. Koberstein, B.Zawta. Reference Ranges for Adults and Children.
Pre-Analytical Considerations. Roche 2008
Method Insert. Cobas Integra 400/800, Cobas c systems
S.J. Soldin, C.Brugnara, E.C.Wong. Pediatric Reference Ranges. AACC Press
2003
V.Matos, G.Melle, O.Boulat et al. Urinary phosphate/creatinine,
calcium/creatinine and ersioon m/creatinine ratios in a healthy pediatric
population. The Journal of Pediatrics, volume 131, number 2
Burtis, Ashwood, Bruns. Tietz Textbook of Clinical Chemistry and Molecular
Diagnostics. Elsevier Saunders 2012
D.Groche, W. Hoeno et al. Standardisation of Two Immunological HbA1c
Routine Assays According to the New IFCC Reference Method. Abstract No:
T-SA-055 at the 18th International Congress of Clinical Chemistry and
Laboratory Medicine, Oct 20-25, 2002, Kyoto, Japan
Lk - 21 -/ 23
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
7
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
K.Kallion, K.Reimand, A.Orav. Comparison of the IgG index and oligoclonal
IgG bands in CSF: finding out ersioo cut-off value for IgG index. Abstract
No: P 29 at the 31th Nordic Congress in Clinical Chemistry, June 14-18,
Helsinki, Finland
8 H.Keller. Klinisch-chemische Labordiagnostic für die Praxis. Stuttgart, New
York:Thieme, 2nd edition, 1991
9 K.de Boeck, M.Wilschanski, C.Castellani et al. Cystic fibrosis: terminology
and diagnostic algorithms. Thorax 2006; 61:627-635
10 DakoCytomation. Cystatin C ersioo infoleht
11 Nordic Reference Interval Porject (NORIP), www.furst.no/norip/
12 KD:IGO (Kidney Disease: Improving Global Outcomes), Kidney Int 2005; 67:2089-100
13 Brunzel NA. Fundamentals of Urine and Bodyfluid Analysis. Saunders 2004
14 Randox Zinc Colorimetric Method Cat. No. ZN 2341 Reagent Information
15 Eesti 2. Tüüpi diabeedi juhend 2008
16 Eesti südame-ja veresoonkonna haiguste preventsiooni juhised, 2006
17 Tinity Biotech. Angiotensin Converting Enzyme (ACE). Procedure 305-UV,
2007-09
18 Elecsys and Cobas e analyzers, Method Sheets
19 Reference Manual for ABL 800 series
20 McPherson RA, Pincus MR. Henry’s Clinical Diagnosis and Management by
Laboratory Methods. Saunders 2007
21 Mitte-Hodgkini lümfoomi raviprotokolli NHL BFM 90. Ägeda
lümfoleukeemia retsidiivi raviprotokolli ALL REZ BFM 90
22 Vendt, N. Rauapuudus ja rauapuudusaneemia 9-12 kuu vanustel imikutel
Eestis. Doktoriväitekiri 2008
23 EV Liiklusseadus, jõustunud 01.02.2001
24 Lewis SM, Bain BJ, Bates I. Dacie and Lewis Practical Haematology.
Churchill Livingstone 2001
25 Binding Site Freelite Human Kappa Free Kit for use on the Roche Cobas
Integra, mai 2008
26 Meisner, M. Procalcitonin (PCT). Thieme 2000.
27 K/DOQI clinical practice guidelines for chronic kidney disease: evaluation,
classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1266
28 T.E. Young, B. Mangum, Neofax 2008
29 Eesti Kardioloogide Selts, Eesti Laborimeditsiini Ühing. Müokardiinfarkti
diagnoosimise uuendatud kriteeriumid 2010, Eesti Arst 2010; 89(5):375−377
30 Siemens, Syva EMIT Tacrolimus Assay
31 BioRad. ALA/PBG by column test, April 2003
32 Immulite Compendium, 2007
33 Fisher DA. Endocrinology. Test selection and interpretation. Nichols Institute,
2007
34 RIA metoodika
35 Clinical Lab Reference Guide, 2006
36 Diagnostics of Endocrine Function in Children and Adolescents, 1996
37 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure, 2008
38 Paediatric Endocrinology, 2004
39 Architect System, method sheet, Abbott
Lk - 22 -/ 23
SA TARTU ÜLIKOOLI KLIINIKUM
ÜHENDLABOR
KVALITEEDIKÄSIRAAMAT
Tähis
Viide
Versioon
TÜL-14.5
PÜL-14
10
40 Rybak M, Lomaestro B et al. Therapeutic monitoring of vancomycin in adult
patients: A Consensus Rewiew of the American Society of Health-System
Pharmacists, the Infectious Diseases Society of America and the Society of
Infetious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98
41 IDS-iSYS IGF-1 Reference Range
42 IDS-iSYS method sheets
43 Krüger C, Rauh M., Dörr H. Immunoreactive renin concentrations in healthy
children from birth to adolescence. Clinica Chimica Acta 1998; 274: 15-27
44 CALIPER database (www.caliperdatabase.com)
45 Novanet method sheet
46 Castagna G et al. Reference Range of serum calcitonin in pediatric population. J Clin
Endocrin Metabolism, March 2015
47 Povisen J, Samonson MH. Fecal calprotectin in healthy children from 0 to 4 years,
ImmunoDiagnostics no7, 2013
Exchanges compared to version 09
Added:
Betahydroxybutyrate
Calprotectin
Cortisol in saliva
Oxalic acid in urine
Citrate in urine
Metanephrine
Normetanephrine
Reason
New analysis in United Laboratories
New quantitative analysis
New analysis forwarded to other laboratory
New analysis forwarded to other laboratory
New analysis forwarded to other laboratory
New analysis forwarded to other laboratory
New analysis forwarded to other laboratory
Exchanged:
Vitamiin B12
Homocystein
Folate
Phosphate
IgG subclasses 1–4
Potassium
Alcaline phosphatase
Chromogranin A
ALAT
ASAT
Alpha-fetoprotein
Creatinin
Calcitonin
Lipoprotein a
Lk - 23 -/ 23
Reviewed pediatric reference ranges according to
CALIPER study; new egent generation
Added pediatric reference ranges according to
CALIPER study
Reviewed pediatric reference ranges according to
CALIPER study
Reviewed pediatric reference ranges according to
CALIPER study
Method changed
Changed according to new data from literature
Pediatric reference ranges changed according to
CALIPER study, lower reference limit added
Manufacturer specified reference ranges
New reagent application
New reagent application
Manufacturer specified reference ranges
New ensymatic method
New method, reference ranges specified according
to manufacturer, pediatric reference ranges
according to literature
Manufacturer specified reference ranges, new units